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Abstract
Background: In the REMoxTB study of 4-month treatment-shortening regimens containing moxifloxacin
compared to the standard 6-month regimen for tuberculosis, the proportion of unfavourable outcomes for
women was similar in all study arms, but men had more frequent unfavourable outcomes (bacteriologically or
clinically defined failure or relapse within 18 months after randomisation) on the shortened moxifloxacin-
containing regimens. The reason for this gender disparity in treatment outcome is poorly understood.
Methods: The gender differences in baseline variables were calculated, as was time to smear and culture
conversion and Kaplan-Meier plots were constructed. In post hoc exploratory analyses, multivariable logistic
regression modelling and an observed case analysis were used to explore factors associated with both gender
and unfavourable treatment outcome.
Results: The per-protocol population included 472/1548 (30%) women. Women were younger and had lower
rates of cavitation, smoking and weight (all p < 0.05) and higher prevalence of HIV (10% vs 6%, p = 0.001).
They received higher doses (mg/kg) than men of rifampicin, isoniazid, pyrazinamide and moxifloxacin (p ≤ 0.
005). There was no difference in baseline smear grading or mycobacterial growth indicator tube (MGIT) time
to positivity. Women converted to negative cultures more quickly than men on Lowenstein-Jensen (HR 1.14,
p = 0.008) and MGIT media (HR 1.19, p < 0.001). In men, the presence of cavitation, positive HIV status, higher
age, lower BMI and ‘ever smoked’ were independently associated with unfavourable treatment outcome. In
women, only ‘ever smoked’ was independently associated with unfavourable treatment outcome. Only for
cavitation was there
a gender difference in treatment outcomes by regimen; their outcome in the 4-month arms was significantly
poorer compared to the 6-month treatment arm (p < 0.001). Women, with or without cavities, and men
without cavities had a similar outcome on all treatment arms (p = 0.218, 0.224 and 0.689 respectively). For all
other covariate subgroups, there were no differences in treatment effects for men or women.
Conclusions: Gender differences in TB treatment responses for the shorter regimens in the REMoxTB study
may be explained by poor outcomes in men with cavitation on the moxifloxacin-containing regimens. We
observed that women with cavities, or without, on the 4-month moxifloxacin regimens had similar outcomes
to all patients on the standard 6-month treatment. The biological reasons for this difference are poorly
understood and require further exploration.
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Background
Tuberculosis (TB) is amongst the leading causes of
death in reproductive-age women. In 2014, there were
3.2 million incident TB cases in women and almost half
a million deaths [1]. In pregnant women, TB is associ-
ated with significant increases in premature birth, low
birth weight and death. In those co-infected with HIV,
the risk of active TB is high, and there is a threefold risk
of mother and child death [2].
While men are notified as having higher incident
TB (5.4 million in 2015), and have higher mortality
(16.5% vs 15%), there is a wide-ranging variation in
gender differences geographically, and mortality is
roughly equal in areas of highest HIV co-infection in
Africa [1]. It is uncertain whether, in settings where
there are low levels of HIV, women are biologically
less susceptible to TB infection and reactivation or
whether gender differences in TB incidence may re-
flect gender-specific sociocultural factors influencing
TB exposure and/or access to healthcare [3, 4].
Most gender-specific TB research has focussed on dif-
ferences in women’s access to healthcare and subsequent
delays in seeking health services, with one study finding
the status of being a married woman, a housewife or be-
ing a woman as being significantly associated with diag-
nostic delays [5]. There is evidence that women, once
enrolled in healthcare, are more likely than men to
adhere to the full course of treatment resulting in
better treatment outcomes [6]. However, there are
limited and sometimes conflicting data on gender dif-
ferences in TB treatment responses and there may be
specific factors, affecting either gender, influencing re-
sponses to treatment [7–9].
In the REMoxTB study of 4-month-treatment shorten-
ing regimens containing moxifloxacin, the proportion of
favourable outcomes for women on the moxifloxacin-con-
taining arms was similar to those on the standard
6-month treatment arm and would be considered
non-inferior [10]. However, male patients, who comprised
70% of the study population, had significantly more un-
favourable outcomes on the moxifloxacin-containing regi-
mens. Specifically, while 8% of both males and females
had unfavourable outcomes on the control regimen, male
vs female breakdown of unfavourable rates for the
isoniazid-moxifloxacin arm was 19% vs 7% and for the
ethambutol-moxifloxacin regimen was 23% vs 13%. Al-
though the study was not designed or powered to detect
differences in treatment outcome by gender, the biological
reasons for the observed gender disparity remain unclear
and warrant further exploration.
The aim of this analysis was to better understand the bio-
logical and epidemiological factors associated with gender
differences in TB treatment responses to inform future TB
treatment and targeted public health interventions.
Methods
We undertook an analysis of the REMoxTB study data-
base [11]. Patients included in this secondary analysis
were those in the pre-specified per-protocol population
in whom the gender-by-treatment interaction was de-
tected in the main REMoxTB study [10]. This was the
primary analysis population for the trial including pa-
tients who had adhered to at least 80% of study drug.
Patient treatment
Adult patients with sputum smear positive for acid-fast
bacilli (AFB) were invited to be screened for enrolment to
the REMoxTB study; a placebo-controlled, randomised,
double-blind, phase 3 trial to test the non-inferiority of
two experimental 4-month treatment arms containing
moxifloxacin compared to standard 6-month treatment
(see below). AFB-positive smears were confirmed on a
new sputum sample in the study laboratory and additional
blood and medical history were collected at the screening
to determine patients’ eligibility, which are described else-
where [10]. Patients with HIV infection could enrol with a
CD4 > 250 cells/μL. Study sites were in Africa, Asia and
Central America. Those eligible and consenting to enrol-
ment in the study were randomised to receive the control
regimen—2 months of rifampicin (R), isoniazid (H), eth-
ambutol (E) and pyrazinamide (Z), followed by 4 months
of rifampicin and isoniazid 2EHRZ/4HR —or one of the
two experimental arms in which moxifloxacin (M) re-
placed either ethambutol (2MHRZ/2MHR; the
isoniazid-arm) or isoniazid (2EMRZ/2MR; the ethambutol
arm). Drug dosing was stratified by patient weight for ri-
fampicin (< 45 kg, 450 mg; ≥ 45 kg, 600 mg), pyrazinamide
(< 55 kg, 1000 mg; ≥ 55–75 kg, 1500 mg; > 75 kg,
2000 mg), and ethambutol (< 40 kg, 15 mg/kg rounded to
nearest 100 mg; 40–55 kg, 800 mg; > 55–75 kg, 1200 mg;
> 75 kg, 1600 mg), while patients received moxifloxacin
400 mg and isoniazid 300 mg, all according to their rando-
mised allocated regimen.
Microbiology
Patients enrolled in the REMoxTB study provided two
sputum samples prior to commencing study drug. Fur-
ther sputum samples were collected at regular study
visits: weekly during the first 8 weeks of intensive phase
treatment, at monthly visits until completion of study
treatment at 6 months and three monthly for a further
12 months, with two samples being collected at each
visit in the post-treatment phase. Each sputum sample
was processed for smear microscopy and culture both
on solid and in liquid media as per the
REMoxTB-specific laboratory manual [12]. In brief, spu-
tum samples were decontaminated and stained using
Ziehl-Neelsen method and graded according to ATS
guidelines as a semi-quantitative measure of
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mycobacterial burden [13]. Sputum samples were proc-
essed for culture on solid Lowenstein-Jensen (LJ)
medium and in the fully automated BACTEC Mycobac-
terial Growth Indicator Tube system (MGIT; BBL™
MGIT™ 960, Becton Dickinson (BD) Microbiology Sys-
tems, Sparks, MD, USA). Time to detection (TTD) was
recorded as a measure of mycobacterial burden. Drug
susceptibility was performed on all isolates, and patients
with multi-drug resistant TB, i.e. resistance to rifampicin
± isoniazid, were excluded.
Statistical analyses
Clinical trial data were recorded in the study database
along with patient demographics: gender, age, weight
and individual drug dose per kilogramme, HIV status
and smoking history. The extent of lung disease was
quantified using a binary variable for cavitation (yes/no).
In addition, Ralph et al. scoring was performed which
provides a score out of 140 comprising percentage of
lung involvement evident on chest radiograph with an
additional 40 points for those with cavitation [14]. Treat-
ment outcomes were as defined by the REMoxTB study
in which the primary efficacy outcome was the propor-
tion of patients who had bacteriologically or clinically
defined failure or relapse within 18 months after ran-
domisation (a composite unfavourable outcome). Differ-
ences in baseline characteristics, including mycobacterial
burden, between males and females were compared
using chi-squared (χ2) and Mann-Whitney U test.
Kaplan-Meier plots were constructed to compare male
and female time to smear and culture conversion, from
randomisation to the study visit of the first negative re-
sult, summarised by a hazard ratio (HR) and compared
using the logrank test. Factors found to be associated
with gender (p < 0.1) were then included in a multivari-
able logistic regression model for unfavourable outcome,
separately for men and women. Treatment effects within
subgroups defined by covariates independently associ-
ated with outcome were explored, and an observed case
analysis was conducted. All these analyses are post hoc
and considered exploratory with no adjustments made
for multiple testing. All analyses were conducted in Stata
Version 14.0.
Results
The per-protocol population of the REMoxTB study
comprised 1548 patients, 472 (30%) of whom were fe-
male. Female patients were younger and had a higher
BMI. They had lower rates of cavitation and smoking.
Females received higher doses of rifampicin (11.28 mg/
kg vs 10.99 mg/kg; p = 0.005), isoniazid (6.36 mg/kg vs
5.76 mg/kg; p = < 0.001), pyrazinamide (23.26 mg/kg vs
22.42 mg/kg; p < 0.001) and moxifloxacin (8.48 mg/kg
vs 7.68 mg/kg; < 0.001), but not for ethambutol which
had a higher dose in men (17.39 mg/kg vs 17.58 mg/kg;
p = 0.018). Compared to males, females had higher
prevalence of HIV (10% vs 6%; p = 0.001); but CD4 cell
counts were comparable (437 and 405 cells/μL, p =
0.32) (see Table 1).
There was no difference in pre-treatment smear grad-
ings and MGIT time to positivity (TTP) (Table 1). The
median LJ TTD was 14 days, with an interquartile range
of 14–21 days, for both women and men, but there was
a significant difference in their rankings with a lower LJ
time to detection (TTD) suggesting higher mycobacterial
burden in women (p = 0.04). Women were faster to con-
vert to culture negative than men on both LJ (HR 1.14;
0.008) and in MGIT media (HR 1.19; p < 0.001). There
was no difference in time to smear conversion (HR 1.07;
p = 0.14). Kaplan-Meier plots are shown in Fig. 1.
Significant univariable baseline factors associated with
an unfavourable outcome included cavitation (OR 2.19,
p < 0.001), a current/ex-smoker (OR 2.07, p < 0.001), a
low BMI (under 18.5 vs 18.5 and above) (OR 1.53, p =
0.004), being older (30 years and under vs over 30 years)
(OR 1.6, p = 0.003) and HIV (OR 2.26, p < 0.001) and
were included in the final adjusted logistic regression
models for unfavourable outcome including treatment
arm, for men and women separately. Drug dosing and
baseline smear and culture results were not significantly
associated with unfavourable outcome and were not in-
cluded in the model. Ralph scoring, which includes a
measure of the percentage of lung involvement in
addition to the binary cavity variable, showed borderline
evidence that men had a higher overall percentage of
lung involvement than women (21.1% vs 19.7%; p =
0.05), but inclusion of this variable in the model did not
improve the overall fit of the models when considered in
place of the binary cavitation variable. Results are shown in
Tables 2 and 3. For men, all factors included remained sig-
nificantly associated with unfavourable outcome in multi-
variable analysis, except for race. For women, only current/
ex-smoking status was significantly associated with the un-
favourable response. No significant treatment-by-covariate
interactions were observed in the multivariable models,
which might have been expected given the small numbers
in each subgroup.
In exploring the treatment effects within subgroups de-
scriptively, cavitation emerged as the only covariate whose
statistical significance differed substantially between gen-
ders in terms of treatment outcomes by regimen. Men
with cavities had significantly poorer outcomes compared
to women with cavities (19% vs 9%, p < 0.001; Table 4). In
contrast, men and women without cavitation had similar
treatment outcomes (both 9%, p = 0.975). Men with
cavities had worse treatment outcomes than men without
cavities and had significantly poorer outcomes on the
experimental arms compared to control (p < 0.001;
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Table 5). However, women with cavities had no difference
in treatment outcome compared to women without cav-
ities (Table 4), and women, with or without cavities, and
men without cavities had similar treatment outcomes
regardless of the treatment regimen (p = 0.218, 0.224 and
0.689 respectively).
To ensure that this result is not impacted by missing
cavitation results, we repeated these analyses using im-
puted values (N = 148) employing a multiple imputation
approach, and this produced similar results (data not
shown). No other treatment effect differences across co-
variate subgroups within gender including HIV status,
smoking and BMI were observed to explain the
gender-by-treatment interaction found in the REMoxTB
study (see Additional file 1: Tables S1).
Discussion
Women receiving 4-month moxifloxacin-containing reg-
imens in the REMoxTB study had similar outcomes to
those on 6-month control regimens. This held true for
all covariate subgroups of women including HIV, smok-
ing and low BMI and seems biologically plausible as
women responded faster to TB treatment than men, des-
pite comparable pre-treatment mycobacterial burdens.
In contrast, the 4-month regimens, men had a signifi-
cantly worse outcome compared to standard 6-month
therapy, particularly the ethambutol-containing regimen.
Cavitation was the only baseline characteristic measured
which could potentially explain the observed difference
in treatment outcomes between men and women.
Our analyses show that failure in the REMoxTB study
was driven by poorer outcomes in men with cavitation
in the moxifloxacin-containing arms. Importantly, men
without cavities and women, with or without cavities,
had similar outcomes in the moxifloxacin-containing
and standard regimens. In addition to cavitation, men
had poorer treatment outcomes on the experimental
arms compared to control in all other covariate sub-
groups. While age, BMI, smoking status and HIV status
were associated with an unfavourable outcome in males,
they could not explain the different outcome in the indi-
vidual treatment regimens. Similarly, for women, a his-
tory of smoking increased the hazard of a poor outcome,
but there was no difference in outcomes across treat-
ment regimens.
It is already established in a previous paper from our
group that cavities visible on posterior-anterior chest
radiograph are associated with the mycobacterial load as
measured by time to positivity (TTP) and directly related
to the size of the cavity [15]. The rate of decline of myco-
bacterial burden in that paper was unrelated to baseline
load suggesting that patients with higher mycobacterial
burdens at baseline would take longer to culture convert.
However, in the current study, while the poor outcomes
of men with cavitation were the only factor which may in
part possibly explain the gender-by-treatment interaction,
males and females had comparable mycobacterial burdens
as measured by MGIT TTP prior to starting the
a
b
c
Fig. 1 Kaplan-Meier estimates of time to a smear, b LJ and c MGIT
culture conversion
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treatment, yet women were faster to culture convert. The
significant difference in the mycobacterial burden on LJ
was more likely related to the ranking of categorical TTD
data, recorded weekly than any real difference. In any case,
this suggested a higher mycobacterial burden in women
and would therefore have been expected to favour males.
Furthermore, although we did not measure cavity volume
specifically, and while there was borderline evidence of a
higher percentage of lung involvement for men compared
to women, this additional information did not improve
the fit of our statistical model.
Cavitation has previously been identified as a risk fac-
tor for poor outcomes in TB treatment regimens, but
these have not been stratified by gender [16]. The poor
outcome of males with cavities on the experimental regi-
mens compared to females with cavities cannot easily be
explained. It may be that males had a higher volume of
cavities, which is a factor that is not measured by the
Ralph score, as this measure includes a single binary
‘penalty’ for cavities that is added to the score for per-
centage lung involvement. Studies of TB immunopathol-
ogy have identified matrix-metalloproteinases as crucial
factors controlling the pulmonary extracellular matrix
involved in cavity formation [17]. A recent study of the
collagenase MMP-8 in plasma has shown this to be
higher in males than in females which may support
greater cavitation in male patients and deserves further
consideration, along with other potential gender-specific
immunological factors which might explain the findings
of this study [18].
An earlier randomised control trial comparing
4-month and 6-month standard regimens in 394 pa-
tients, including 154 women, with non-cavitary disease,
and who culture converted after 2 months standard
treatment, was halted due to an unacceptable failure rate
in the 4-month arms (7.0% vs 1.6%). This suggests that
cavitation may not entirely explain the gender difference
in treatment outcome observed in the REMoxTB study,
however, again, the results of this study were not re-
ported by gender [19]. A re-analysis of previous trial
data from the UK MRC comparing 4- and 6-month regi-
mens also identified higher rates of failure in the shorter
regimens (5.9% vs 0%) [20]. However, unpublished data
from two previous MRC trials involving unsuccessful
Table 2 Treatment and covariate effects on unfavourable outcome for men (N = 974)
r/n OR (unadjusted), 95% CI p aOR (adjusted), 95% CI p
Treatment
HRZE 30/326 (33) 1.0
2MHRZ/2MHR 55/312 (32) 2.22 (1.36–3.62) 0.001 2.24 (1.37–3.65) 0.001
2EMRZ/2MR 78/336 (35) 3.31 (2.07–5.29) < 0.001 3.31 (2.07–5.28) < 0.001
Age
≤ 30 years 58/435 1.0 1.0
> 30 years 105/539 1.46 (1.00–2.12) 0.045 1.48 (1.02–2.14) 0.037
BMI
< 18.5 105/547 1.0 1.0
≥ 18.5 58/427 0.65 (0.45–0.93) 0.020 0.64 (0.44–0.92) 0.017
Race
Asian 50/311 1.0
Black 70/430 0.85 (0.55–1.32) 0.469 – –
Mixed race and Caucasian 43/233 0.97 (0.58–1.61) 0.902
Smoking
Never smoked 39/334 1.0 1.0
Ever smoked 124/640 1.61 (1.04–2.49) 0.034 1.60 (1.07–2.40) 0.023
HIV
Negative 143/922 (95) 1.0 1.0
Positive 20/52 4.26 (2.22–8.18) < 0.001 3.97 (2.12–7.42) < 0.001
Cavities
No cavities 16/198 1.0 1.0
Cavities 147/776 2.78 (1.59–4.85) < 0.001 2.78 (1.59–4.84) < 0.001
r number with unfavourable outcome
n total in category
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4-month regimens, including one containing moxifloxa-
cin, indicated that women had significantly better out-
comes than men in an analysis stratified by cavitation, as
in our study (Personal communication: Professor An-
drew Nunn, MRC Clinical Trials Unit at UCL).
Gender-specific pharmacodynamics might potentially
explain the observed differences in the treatment out-
come. In the REMoxTB study, women, on average, re-
ceived small increased doses of four of five study drugs,
including moxifloxacin, known to be essential for bacter-
ial sterilisation and cure. Increased dosing may therefore
go some way to explaining the faster bacteriological re-
sponse to treatment, but these were not found to be sig-
nificantly associated with treatment outcome on
univariable analyses. No gender difference in the
pharmacokinetics of moxifloxacin has been described to
explain the differences in unfavourable outcome between
men and women with and without cavitation on the
moxifloxacin-containing regimens. Poor outcomes on
the ethambutol arms may be due to the superior bacteri-
cidal effect of isoniazid or the presence of three drugs
over a 4-month period. Compliance with study regimens
may also be a factor. To be included in the per-protocol
analysis in which the gender-by-treatment interaction
was identified, all patients had to have taken more than
80% of their medication. However, as data collection was
not sufficiently detailed to address adherence further by
gender, we do not know whether, within the
per-protocol population of the REMoxTB study taking
>80% of study medication, females may have had
Table 3 Treatment and covariate effects on unfavourable outcome for women (N = 426)
r/n OR (unadjusted), 95% CI p aOR (adjusted), 95% CI p
Treatment
HRZE 10/138
2MHRZ/2MHR 11/149 0.98 (0.40–2.43) 0.973 – –
2EMRZ/2MR 18/139 1.93 (0.84–4.39) 0.119
Age
≤ 30 years 20/223 1.0 – –
> 30 years 19/203 0.95 (0.48–1.88) 0.881
BMI
< 18.5 19/189 1.0 – –
≥ 18.5 20/237 1.03 (0.51–2.12) 0.926
Race
Asian 15/135 1.0
Black 9/163 0.39 (0.14–1.08) 0.070 – –
Mixed race and Caucasian 15/128 0.45 (0.14–1.45) 0.182
Smoking
Never smoked 21/292 1.0 1.0
Ever smoked 18/134 2.69 (0.92–7.90) 0.071 2.00 (1.03–3.90) 0.041
HIV
Negative 36/385 1.0 – –
Positive 3/41 1.16 (0.28–4.84) 0.835
Cavities
No cavities 9/110 1.0 – –
Cavities 30/316 1.16 (0.51–2.63) 0.715
Table 4 Unfavourable outcome within gender and subgroups defined by cavities
Cavities (N = 1092) No cavities (N = 308)
Male N (%) Female N (%) Male N (%) Female N (%)
776 (71) 316 (29) 198 (64) 110 (36)
Favourable Un-fav Favourable Un-fav Favourable Un-fav Favourable Un-fav
629 (81) 147 (19) 286 (91) 30 (9) 182 (92) 16 (8) 101 (92) 9 (8)
p < 0.001 p = 0.975
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significantly greater compliance, nearer 100%, compared
to men, or, indeed, vice versa. A previous systematic re-
view of previous studies found a higher likelihood of
compliance amongst females, so it would be important
to consider the potential impact in future studies [6].
Furthermore, we were unable to further stratify compli-
ance by gender and cavitation, and we cannot comment
on whether there were differences in treatment compli-
ance in men and women with cavitation which might ex-
plain the differences observed in the REMoxTB study.
To date, reports of gender differences in outcome have
often been excluded from published clinical trials of
moxifloxacin, and thus, there is limited data on the out-
comes by gender for the many indications of moxifloxa-
cin [21]. Two other clinical trials of fluoroquinolones for
tuberculosis were published at the same time as the
REMoxTB study but neither included analysis by gender
[22, 23]. The US Food and Drug Administration, guide-
lines support reporting of gender differences in the clin-
ical evaluation of drugs and journals are increasingly
introducing editorial policies requiring the reporting of
result by gender [24, 25]. Our observation emphasises
the importance of such policies and supports the report-
ing of outcomes by gender so that we can better under-
stand the factors bearing on these differences. This is
particularly true for studies of moxifloxacin given that it
is commonly used to treat with complicated and/or se-
vere disease including patients intolerant of other
first-line drugs and in patients with TB meningitis.
Although we should bear in mind that these analyses
were all post hoc, considered exploratory and based on
relatively small numbers not powered to detect a
gender-treatment interaction, the findings suggest that
possibly the shorter regimens may be appropriate in fe-
males. Yet, how gender-specific therapy, if indicated,
could be implemented within current standard National
TB Programmes requires operational consideration. Re-
search on gender difference in tuberculosis has thus far
focussed on improving access to healthcare for women,
presuming that, once engaged, women will have greater
adherence to therapy. It is axiomatic that we need to im-
prove patient engagement and adherence to approved
regimens, but our study suggests a greater focus on men
may be required to improve their treatment outcomes.
This is supported by the findings of a recent
meta-analysis that reported men as disadvantaged in
seeking or accessing TB services and suggested that men
were a high-risk group requiring improved access to TB
[4]. Other factors associated with poor outcomes in men
and/or women, including smoking and HIV, should fur-
ther assist in directing public health responses.
Conclusions
Gender differences in TB treatment responses for the
shorter regimens in the REMoxTB study may be explained
by poor outcomes in men with cavitation on the moxifloxa-
cin-containing regimens. We observed that women with
cavities, or without, on the 4-month moxifloxacin regimens
had similar outcomes to all patients on the standard
6-month treatment. The biological reasons for this differ-
ence are poorly understood and require further exploration.
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